Guardant Health, Inc. $GH Shares Bought by Rhumbline Advisers

Rhumbline Advisers increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 5.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 184,724 shares of the company’s stock after buying an additional 9,292 shares during the quarter. Rhumbline Advisers owned about 0.15% of Guardant Health worth $9,613,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Signaturefd LLC boosted its holdings in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after acquiring an additional 213 shares during the period. IFP Advisors Inc lifted its position in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after purchasing an additional 552 shares during the period. SVB Wealth LLC purchased a new position in shares of Guardant Health in the first quarter valued at $54,000. Finally, FNY Investment Advisers LLC acquired a new stake in Guardant Health during the 2nd quarter valued at $62,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GH has been the subject of a number of analyst reports. Wells Fargo & Company initiated coverage on shares of Guardant Health in a research report on Monday, September 22nd. They issued an “overweight” rating and a $72.00 price objective for the company. Citigroup boosted their price target on Guardant Health from $65.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Canaccord Genuity Group set a $100.00 price objective on Guardant Health in a research note on Thursday, October 30th. TD Cowen upped their target price on Guardant Health from $63.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Finally, Mizuho set a $100.00 target price on Guardant Health in a research note on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and a consensus target price of $80.86.

Insiders Place Their Bets

In other news, insider John G. Saia sold 8,996 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $96.25, for a total value of $865,865.00. Following the transaction, the insider directly owned 43,172 shares in the company, valued at approximately $4,155,305. This trade represents a 17.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the sale, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 313,061 shares of company stock valued at $18,989,478. Company insiders own 6.10% of the company’s stock.

Guardant Health Stock Down 3.0%

Shares of NASDAQ GH opened at $105.22 on Tuesday. The stock’s 50 day moving average price is $81.02 and its two-hundred day moving average price is $61.58. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43. The stock has a market capitalization of $13.26 billion, a P/E ratio of -32.78 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same period in the prior year, the company earned ($0.88) earnings per share. The business’s revenue was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.